Clinical trials: Antipsychotics, open to volunteers
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
Cardiovascular Diseases (CVD), Depression Anxiety Disorder
Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)
Psycho-Cardiological Disease studies the complex links between the cardiovascular system and emotions. The two diseases are now the focus of public health organizations, forming a vicious circle of mutual influence.
- Trial name
- NCT07025590
- Testing
- Moderate-intensity continuous movement and Antipsychotics intervention, Antipsychotics intervention(sertraline, escitalopram, fluoxetine, duloxetine, paroxetine, venlafaxine, and fluvoxamine)
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Provincial People's Hospital
Intellectual Disability, Developmental Disability
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease.
- Conditions
- Intellectual Disability, Developmental Disability, Obesity
- Trial name
- METIDD (NCT05744479)
- Testing
- Metformin, Lifestyle Intervention
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Delirium, Epileptics
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with…
- Conditions
- Delirium, Epileptics, Neuroleptics
- Trial name
- NCT05431595
- Testing
- Haloperidol, Chlorpromazine, Valproate
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
First Episose Psychosis, Metabolic Disease
The ATP Project (Antipsychotic-TEP-Psychosis)
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
- Conditions
- First Episose Psychosis, Metabolic Disease, Psychosis; Episode
- Trial name
- ATP (NCT06651112)
- Testing
- Antipsychotic drugs
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Université de Sherbrooke
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Lurasidone Cardiotoxicity, Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.
- Conditions
- Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
- Trial name
- Lurasidone (NCT06695676)
- Testing
- Global Longitudinal Strain
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Schizophrenia, Schizoaffective Disorder
CLOZAPINE Response in Biotype-1
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
- Trial name
- NCT04580134
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 524 people
- Sponsor
- University of Texas Southwestern Medical Center
Psychotic Disorder
Deprescribing Antipsychotics: a Multiple Case Study
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be…
- Trial name
- DEPRESC (NCT07343193)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Tardive Dyskinesia, Intellectual Disability
Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population.
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Trial name
- TD-AIDD (NCT06997198)
- Testing
- Deutetrabenazine Oral Capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
The Danish Region Midt Schizophrenia Cohort
The objective of this study is to recruit patients at the first diagnosis with a schizophrenia spectrum disorder (SSD) and ultra-high risk patients (UHR), defined as patients with drug abuse and psychotic symptoms indicating a…
- Trial name
- RMS (NCT06431009)
- Testing
- Treatment-as-usual
- Where
- 5 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- University of Aarhus
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Psychosis
Immune Mechanisms of Antipsychotic Treatment Response
The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis…
- Trial name
- IMAT (NCT06687694)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- King's College London
Functional Dyspepsia
Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia
The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia.
- Trial name
- NCT07008235
- Testing
- Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Md. Moktadirul Hoque Shuvo
Schizophrenia
iTBS for Increased Appetite Induced by Antipsychotics
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to…
- Trial name
- NCT05783063
- Testing
- Active iTBS
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Central South University
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Schizophrenia Disorders
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia
The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium…
- Trial name
- NCT06924255
- Testing
- Xanomeline and Trospium Chloride
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Collaborative Neuroscience Research, LLC
Scizophrenia
Carbergoline for Antipsychotic Induced Hyperprolactinemia.
The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia.
- Trial name
- NCT07386080
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Zealand University Hospital